Sometimes people are sober and in recovery from alcohol use disorder (AUD) for several years, but relapse. Why? Alcohol use disorder is a chronic, often relapsing medical condition affecting millions ...

January 2016, a decade ago this week, was the last time I drank. Not that I knew it was the last drink at the time. “Never again” was as much part of my vocabulary as “shall we get another?” (a ...

January 2016, a decade ago this week, was the last time I drank. Not that I knew it was the last drink at the time. “Never again” was as much part of my vocabulary as “shall we get another?” (a ...

I need to remind myself that relapsing will not help anything. Picking up again may bring some immediate comfort in these disorienting, fraught, and perilous times. But that comfort is illusory, a ...

JACKSONVILLE, Fla. — For many, the holiday season brings celebration, travel and time with loved ones. But for people in recovery from substance use, it can also bring disrupted routines, heightened ...

Please provide your email address to receive an email when new articles are posted on . Many clinicians overlook neurohormonal and metabolic adaptations that make weight loss difficult. Obesity ...

In a trial, rituximab demonstrated clinical efficacy in reducing proteinuria in patients with FRNS or SDNS. Intravenous rituximab is safe and effective in patients with frequently relapsing nephrotic ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral inflammation and persistent immune activation within the central nervous system, ...

This review is describing the diagnostic and therapeutic approach to tracheobronchial involvement in relapsing polychondritis (RP), with a focus on differential diagnoses of inflammatory origin. RP is ...

Use the least expensive option of the available treatments (including ublituximab, ocrelizumab and ofatumumab). Take account of administration costs, dosages, price per dose and commercial ...

There is a simple discount patient access scheme for ublituximab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy. Researchers analyzed peripheral ...